Modelling the Genetic Risk in Age-Related Macular Degeneration
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Late-stage age-related macular degeneration (AMD) is a common sight-threatening disease of the central retina affecting approximately 1 in 30 Caucasians. Besides age and smoking, genetic variants from several gene loci have reproducibly been associated with this condition and likely explain a large proportion of disease. Here, we developed a genetic risk score (GRS) for AMD based on 13 risk variants from eight gene loci. The model exhibited good discriminative accuracy, area-under-curve (AUC) of the receiver-operating characteristic of 0.820, which was confirmed in a cross-validation approach. Noteworthy, younger AMD patients aged below 75 had a significantly higher mean GRS (1.87, 95% CI: 1.69-2.05) than patients aged 75 and above (1.45, 95% CI: 1.36-1.54). Based on five equally sized GRS intervals, we present a risk classification with a relative AMD risk of 64.0 (95% CI: 14.11-1131.96) for individuals in the highest category (GRS 3.44-5.18, 0.5% of the general population) compared to subjects with the most common genetic background (GRS -0.05-1.70, 40.2% of general population). The highest GRS category identifies AMD patients with a sensitivity of 7.9% and a specificity of 99.9% when compared to the four lower categories. Modeling a general population around 85 years of age, 87.4% of individuals in the highest GRS category would be expected to develop AMD by that age. In contrast, only 2.2% of individuals in the two lowest GRS categories which represent almost 50% of the general population are expected to manifest AMD. Our findings underscore the large proportion of AMD cases explained by genetics particularly for younger AMD patients. The five-category risk classification could be useful for therapeutic stratification or for diagnostic testing purposes once preventive treatment is available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Complement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 1×
“To date, effective therapeutic intervention is available for active NV, while GA still remains untreatable [4,5].”
BackgroundInternal validation of predictive models
Steyerberg, E. W., Harrell, F. E., Borsboom, G. J. J. M., Eijkemans, M. J. C., Vergouwe, Y., & Habbema, J. D. F. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00341-9 · Cited by 2,746
Causes and Prevalence of Visual Impairment Among Adults in the UnitedStates
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.477 · Cited by 2,616
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961 · cited 1×
“Stereo fundus photographs were graded according to standardized classification systems as described previously [9,42,43].”
Bird, A. C., Bressler, N. M., Bressler, S. B., Chisholm, I. H., Coscas, G., Davis, M. D., de Jong, P. T. V. M., Klaver, C. C. W., Klein, B. E. K., Klein, R., et al. (1995) · Survey of Ophthalmology · doi:10.1016/s0039-6257(05)80092-x · Cited by 1,926
Age-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379
The AMD Genetics Clinical Study Group, Gold, B., Merriam, J. E., Zernant, J., Hancox, L. S., Taiber, A. J., Gehrs, K., Cramer, K., Neel, J., Bergeron, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1750 · Cited by 1,075
Complement C3 variant and the risk of age-related macular degeneration
Yates, J. R. W., Sepp, T., Matharu, B. K., Khan, J. C., Thurlby, D. A., Shahid, H., Clayton, D. G., Hayward, C., Morgan, J., Wright, A. F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072618 · Cited by 829
Age-related macular degeneration
de Jong, P. T. V. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062326 · Cited by 787
Genotype score in addition to common risk factors for prediction of type 2 diabetes
Meigs, J. B., Shrader, P., Sullivan, L. M., McAteer, J. B., Fox, C. S., Dupuis, J., Manning, A. K., Florez, J. C., Wilson, P. W. F., D'Agostino, R. B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804742 · Cited by 759 · cited 1×
“However, such an approach may not be particularly effective in the presence of greatly differing effect sizes of the respective variants [25].”
BackgroundChen, W., Stambolian, D., Edwards, A. O., Branham, K. E., Othman, M., Jakobsdottir, J., Tosakulwong, N., Pericak-Vance, M. A., Campochiaro, P. A., Klein, M. L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912702107 · Cited by 506 · cited 7×
“Model1 Variants2 R2 AUC 13-SNP model 1,2,3,4,5,6,7,8,9,10,11,12,13 0.2475 0.820 - TIMP3 1,2,3,4,5,6,7,8,9,10,11,12 0.2475 0.820 - PLA2G12A 1,2,3,4,5,6,7,8,9,11,12 0.2454 0.819 - APOE 1,2,3,4,5,6,7,10,11,12 0.2411 0.816 - LIPC3 1,2,3,4,5,6,7,8,9,10 0.2457 0.820 1SNPs from one additional locus at a time were omitted fro…”
BackgroundInfluentialGenetic Association of Apolipoprotein E with Age-Related Macular Degeneration
Klaver, C. C. W., Kliffen, M., van Duijn, C. M., Hofman, A., Cruts, M., Grobbee, D. E., van Broeckhoven, C., & de Jong, P. T. V. M. (1998) · The American Journal of Human Genetics · doi:10.1086/301901 · Cited by 498
Hughes, A. E., Orr, N., Esfandiary, H., Diaz-Torres, M., Goodship, T., & Chakravarthy, U. (2006) · Nature Genetics · doi:10.1038/ng1890 · Cited by 467
Seddon, J. M. (2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.3.321 · Cited by 446 · cited 1×
“AMD is a complex disease influenced by genetic and environmental factors with estimates of heritability varying from 45% to 71% [6].”
BackgroundNeale, B. M., Fagerness, J., Reynolds, R., Sobrin, L., Parker, M., Raychaudhuri, S., Tan, P. L., Oh, E. C., Merriam, J. E., Souied, E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912019107 · Cited by 442
Variation in complement factor 3 is associated with risk of age-related macular degeneration
Maller, J. B., Fagerness, J. A., Reynolds, R. C., Neale, B. M., Daly, M. J., & Seddon, J. M. (2007) · Nature Genetics · doi:10.1038/ng2131 · Cited by 437 · cited 1×
“These studies identified risk-associated variants in or near three additional complement genes including the complement component 2 (C2)/complement factor B (CFB) [15], complement component 3 (C3) [16,17] and complement factor I (CFI) [18].”
BackgroundVariation near complement factor I is associated with risk of advanced AMD
Fagerness, J. A., Maller, J. B., Neale, B. M., Reynolds, R. C., Daly, M. J., & Seddon, J. M. (2009) · European Journal of Human Genetics · doi:10.1038/ejhg.2008.140 · Cited by 357
Li, M., Atmaca-Sonmez, P., Othman, M., Branham, K. E. H., Khanna, R., Wade, M. S., Li, Y., Liang, L., Zareparsi, S., Swaroop, A., et al. (2006) · Nature Genetics · doi:10.1038/ng1871 · Cited by 354 · cited 1×
“Fine-mapping studies and functional analyses at the CFH locus indicate at least three independent risk variants [8–13].”
BackgroundSeddon, J. M., Reynolds, R., Maller, J., Fagerness, J. A., Daly, M. J., & Rosner, B. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3064 · Cited by 285 · cited 4×
“446 individuals of which 279 progressed to AMD) [26].”
BackgroundResultInfluential(2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.5.671 · Cited by 283
Yu, Y., Bhangale, T. R., Fagerness, J., Ripke, S., Thorleifsson, G., Tan, P. L., Souied, E. H., Richardson, A. J., Merriam, J. E., Buitendijk, G. H. S., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr270 · Cited by 254
Fritsche, L. G., Lauer, N., Hartmann, A., Stippa, S., Keilhauer, C. N., Oppermann, M., Pandey, M. K., Köhl, J., Zipfel, P. F., Weber, B. H. F., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq399 · Cited by 203
Self-citationSeddon, J. M., Reynolds, R., Yu, Y., Daly, M. J., & Rosner, B. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.04.029 · Cited by 198 · cited 1×
“, Table 4) [36], although it needs to be noted that the models used in our and the published study differ in the sense that Table 4.”
Result
Cited by
Winkler, T. W., Grassmann, F., Brandl, C., Kiel, C., Günther, F., Strunz, T., Weidner, L., Zimmermann, M. E., Korb, C. A., Poplawski, A., et al. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-00760-7 · Cited by 138
Self-citationHallam, D., Collin, J., Bojic, S., Chichagova, V., Buskin, A., Xu, Y., Lafage, L., Otten, E. G., Anyfantis, G., Mellough, C., et al. (2017) · Stem Cells · doi:10.1002/stem.2708 · Cited by 75
Genetics and genetic testing for age-related macular degeneration
Warwick, A., & Lotery, A. (2018) · Eye · doi:10.1038/eye.2017.245 · Cited by 67
Tzoumas, N., Hallam, D., Harris, C. L., Lako, M., Kavanagh, D., & Steel, D. H. W. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2020.10.008 · Cited by 33
Metadata
- Authors
- Grassmann, F., Fritsche, L. G., Keilhauer, C. N., Heid, I. M., & Weber, B. H. F.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-05-30
- Volume
- 7
- Issue
- 5
- Pages
- e37979
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2073461896
- Cited by
- 85
- References
- 26
- FWCI
- 10.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.